{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:20:27Z","timestamp":1793488827996,"version":"4.5.0"},"reference-count":290,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vellore Institute of Technology, Vellore"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cardinal features of triple-negative breast cancer (TNBC) are that it is aggressive and does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, presenting significant therapeutic challenges. Recent advances have identified immune checkpoint inhibitors (ICIs), especially anti-PD-1\/PD-L1 agents, as promising treatments for TNBC. Tumor mutational burden (TMB) has been implicated as a promising approach for predicting ICI responses. This review examines the current evidence in favor of TMB as a biomarker, its relationship with ICI efficacy, and future directions in TNBC therapy. We explore the mechanisms linking high TMB to enhanced neoantigen presentation, which leads to improved immune responses and better patient outcomes with ICIs. Additionally, we discuss the role of combination therapies involving ICIs with chemotherapy or poly(ADP-ribose) polymerase inhibitors, and how TMB can guide treatment personalization in TNBC. While TMB shows promise, further research is needed to establish standardized measurement techniques and cutoffs, enhancing its clinical utility in predicting ICI response. Future studies focusing on tumor microenvironment interactions and resistance mechanisms are crucial for advancing precision oncology in TNBC.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01892-9","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:40:20Z","timestamp":1763433620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses"],"prefix":"10.1007","volume":"26","author":[{"given":"Rajdeep","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. K.","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"1","key":"1892_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","volume":"27","author":"FM Howard","year":"2021","unstructured":"Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer. Cancer J. 2021;27(1):8\u201316. https:\/\/doi.org\/10.1097\/PPO.0000000000000500.","journal-title":"Cancer J"},{"issue":"4","key":"1892_CR2","first-page":"457","volume":"6","author":"R Verma","year":"2021","unstructured":"Verma R, Lal Jakhar S, Sharma N, Kumar HS, Beniwal S. Epidemiological profile and clinicopathological correlates of triple negative breast cancer patients at regional cancer centre. Asian Pac J Cancer Care. 2021;6(4):457\u201360.","journal-title":"Asian Pac J Cancer Care"},{"issue":"1","key":"1892_CR3","doi-asserted-by":"publisher","first-page":"045","DOI":"10.23937\/2469-5831\/1510045","volume":"8","author":"S Suvobrata","year":"2022","unstructured":"Suvobrata S, Murtaza A. Triple negative breast cancer prevalence in indian patients over a decade: a systematic review. Int J Clin Biostat Biom. 2022;8(1):045.","journal-title":"Int J Clin Biostat Biom"},{"issue":"4","key":"1892_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/mco.2022.2528","volume":"16","author":"X Du","year":"2022","unstructured":"Du X. Racial disparities in health insurance, triple-negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States. Mol Clin Oncol. 2022;16(4):95.","journal-title":"Mol Clin Oncol"},{"key":"1892_CR5","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","volume":"9","author":"CK Anders","year":"2009","unstructured":"Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73-81.","journal-title":"Clin Breast Cancer"},{"key":"1892_CR6","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.893","author":"C Caglevic","year":"2019","unstructured":"Caglevic C, Anabal\u00f3n J, Soza C, Milla E, Gaete F, Carrasco AM, et al. Triple-negative breast cancer: the reality in Chile and in Latin America. Ecancermedicalscience. 2019. https:\/\/doi.org\/10.3332\/ecancer.2019.893.","journal-title":"Ecancermedicalscience"},{"issue":"6","key":"1892_CR7","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.1002\/cam4.5515","volume":"12","author":"KA Metcalfe","year":"2023","unstructured":"Metcalfe KA, Narod SA, Eisen A, Poll A, Zamani N, McCready D, et al. Genetic testing women with newly diagnosed breast cancer: what criteria are the most predictive of a positive test? Cancer Med. 2023;12(6):7580\u20137. https:\/\/doi.org\/10.1002\/cam4.5515.","journal-title":"Cancer Med"},{"issue":"3","key":"1892_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-010-1148-9","volume":"126","author":"AI Phipps","year":"2011","unstructured":"Phipps AI, Buist DSM, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat. 2011;126(3):671\u20138. https:\/\/doi.org\/10.1007\/s10549-010-1148-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1892_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1084\/jem.20181616","volume":"216","author":"P Tiwari","year":"2019","unstructured":"Tiwari P, Blank A, Cui C, Schoenfelt KQ, Zhou G, Xu Y, et al. Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer. J Exp Med. 2019;216(6):1345\u201358.","journal-title":"J Exp Med"},{"issue":"2","key":"1892_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-009-0591-y","volume":"121","author":"B Maiti","year":"2010","unstructured":"Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat. 2010;121(2):479\u201383. https:\/\/doi.org\/10.1007\/s10549-009-0591-y.","journal-title":"Breast Cancer Res Treat"},{"key":"1892_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107876","volume":"98","author":"M Farshbafnadi","year":"2021","unstructured":"Farshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence. Int Immunopharmacol. 2021;98:107876.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1892_CR12","first-page":"305","volume":"19","author":"M Steiner","year":"2021","unstructured":"Steiner M, Tan AR. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Clin Adv Hematol Oncol. 2021;19(5):305\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"1892_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16(1):100. https:\/\/doi.org\/10.1186\/s13045-023-01497-3.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1892_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14737140.2023.2265059","volume":"23","author":"K Tarekegn","year":"2023","unstructured":"Tarekegn K, Keskinkilic M, Kristoff TJ, Evans ST, Kalinsky K. The role of immune checkpoint inhibition in triple negative breast cancer. Expert Rev Anticancer Ther. 2023;23(10):1095\u2013106. https:\/\/doi.org\/10.1080\/14737140.2023.2265059.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1892_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202317613","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Zhang S, Jiang N, Zhu W, Song D, Liu S, et al. Patient-derived immunocompetent tumor organoids: a platform for chemotherapy evaluation in the context of t-cell recognition. Angew Chemie. 2024. https:\/\/doi.org\/10.1002\/ange.202317613.","journal-title":"Angew Chemie"},{"issue":"4","key":"1892_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.autrev.2019.02.006","volume":"18","author":"SC Funes","year":"2019","unstructured":"Funes SC, de Manrique Lara A, Altamirano-Lagos MJ, Mackern-Oberti JP, Escobar-Vera J, Kalergis AM. Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy. Autoimmun Rev. 2019;18(4):359\u201368.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1892_CR17","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"key":"1892_CR18","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1186\/s12885-018-5020-3","volume":"18","author":"ZS Guo","year":"2018","unstructured":"Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). BMC Cancer. 2018;18:1086.","journal-title":"BMC Cancer"},{"key":"1892_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405491\/full","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1405491\/full.","journal-title":"Front Oncol"},{"issue":"20","key":"1892_CR20","doi-asserted-by":"publisher","first-page":"2306766","DOI":"10.1002\/smll.202306766","volume":"20","author":"Q Wu","year":"2024","unstructured":"Wu Q, Li Z, Zhou X, Wei Z, Ramadan S, Xu Y, et al. Photothermal ferrotherapy-induced immunogenic cell death via iron-based ternary chalcogenide nanoparticles against triple-negative breast cancer. Small. 2024;20(20):2306766.","journal-title":"Small"},{"issue":"10","key":"1892_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41388-023-02934-w","volume":"43","author":"B Xu","year":"2024","unstructured":"Xu B, Sun H, Liu S, Liao L, Song X, Wu Y, et al. IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene. 2024;43(10):693\u2013702.","journal-title":"Oncogene"},{"issue":"1","key":"1892_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","volume":"16","author":"Z Li","year":"2018","unstructured":"Li Z, Qiu Y, Lu W, Jiang Y, Wang J. Immunotherapeutic interventions of triple negative breast cancer. J Transl Med. 2018;16(1):147. https:\/\/doi.org\/10.1186\/s12967-018-1514-7.","journal-title":"J Transl Med"},{"key":"1892_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1641","author":"MC Bourgeois-Daigneault","year":"2018","unstructured":"Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aao1641.","journal-title":"Sci Transl Med"},{"key":"1892_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1061789\/full","author":"A Schreier","year":"2023","unstructured":"Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E. Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2022.1061789\/full.","journal-title":"Front Oncol"},{"issue":"11","key":"1892_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112834","volume":"13","author":"CS Fermaintt","year":"2021","unstructured":"Fermaintt CS, Peramuna T, Cai S, Takahashi-Ruiz L, Essif JN, Grant CV, et al. Yuanhuacine is a potent and selective inhibitor of the basal-like 2 subtype of triple negative breast cancer with immunogenic potential. Cancers (Basel). 2021;13(11):2834.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1892_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122253","volume":"16","author":"S Demirsoy","year":"2024","unstructured":"Demirsoy S, Tran H, Liu J, Li Y, Yang S, Aregawi D, et al. Targeting Tyro3, Axl, and MerTK receptor tyrosine kinases significantly sensitizes triple-negative breast cancer to CDK4\/6 inhibition. Cancers (Basel). 2024;16(12):2253.","journal-title":"Cancers (Basel)"},{"key":"1892_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl8247","author":"P Ji","year":"2022","unstructured":"Ji P, Gong Y, Jin M, Wu H, Guo LW, Pei YC, et al. In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Sci Adv. 2022. https:\/\/doi.org\/10.1126\/sciadv.abl8247.","journal-title":"Sci Adv"},{"issue":"4","key":"1892_CR28","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/jcm12041524","volume":"12","author":"J Lee","year":"2023","unstructured":"Lee J. Current treatment landscape for early triple-negative breast cancer (TNBC). J Clin Med. 2023;12(4):1524.","journal-title":"J Clin Med"},{"key":"1892_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.985886\/full","author":"B Aparicio","year":"2022","unstructured":"Aparicio B, Rep\u00e1raz D, Ruiz M, Llopiz D, Silva L, Vercher E, et al. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.985886\/full.","journal-title":"Front Immunol"},{"key":"1892_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202203019","author":"X Feng","year":"2023","unstructured":"Feng X, Zhang J, Wu L, Lin W, Liu Z, Zhou X, et al. Drug self-delivery nanocubes enhance O2-economized photodynamic-immunotherapy of triple-negative breast cancer by downregulating Wnt\/ \u03b2 -catenin signaling. Adv Healthc Mater. 2023. https:\/\/doi.org\/10.1002\/adhm.202203019.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"1892_CR31","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","volume":"25","author":"SJ Klempner","year":"2020","unstructured":"Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist. 2020;25(1):e147\u201359.","journal-title":"Oncologist"},{"issue":"12","key":"1892_CR32","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808\u201325.","journal-title":"Cancer Discov"},{"issue":"2","key":"1892_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0202","volume":"3","author":"K Parikh","year":"2020","unstructured":"Parikh K, Huether R, White K, Hoskinson D, Beaubier N, Dong H, et al. Tumor mutational burden from tumor-only sequencing compared with germline subtraction from paired tumor and normal specimens. JAMA Netw open. 2020;3(2):e200202.","journal-title":"JAMA Netw open"},{"issue":"15_suppl","key":"1892_CR34","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1200\/JCO.2021.39.15_suppl.9097","volume":"39","author":"T Ikeda","year":"2021","unstructured":"Ikeda T, Oi H, Yoh K, Matsumoto S, Kato T, Nishino K, et al. Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9097\u20139097. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9097.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1892_CR35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/oncotarget.27877","volume":"12","author":"TA O\u2019Meara","year":"2021","unstructured":"O\u2019Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12(5):394\u2013400.","journal-title":"Oncotarget"},{"key":"1892_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111798","author":"JY Kim","year":"2019","unstructured":"Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, et al. Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111798.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"1892_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.21037\/atm.2019.10.116","volume":"7","author":"HX Wu","year":"2019","unstructured":"Wu HX, Wang ZX, Zhao Q, Chen DL, He MM, Yang LP, et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med. 2019;7(22):640\u2013640.","journal-title":"Ann Transl Med"},{"issue":"9","key":"1892_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1629258","volume":"8","author":"D Cao","year":"2019","unstructured":"Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019;8(9):e1629258. https:\/\/doi.org\/10.1080\/2162402X.2019.1629258.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1892_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00164-5","volume":"5","author":"YW Asmann","year":"2021","unstructured":"Asmann YW, Parikh K, Bergsagel PL, Dong H, Adjei AA, Borad MJ, et al. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. NPJ Precis Oncol. 2021;5(1):22.","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"1892_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","volume":"30","author":"J Budczies","year":"2019","unstructured":"Budczies J, Allg\u00e4uer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, et al. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol. 2019;30(9):1496\u2013506.","journal-title":"Ann Oncol"},{"issue":"5","key":"1892_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11604-021-01230-5","volume":"40","author":"N Ota","year":"2022","unstructured":"Ota N, Yoshimoto Y, Darwis NDM, Sato H, Ando K, Oike T, et al. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol. 2022;40(5):534\u201341. https:\/\/doi.org\/10.1007\/s11604-021-01230-5.","journal-title":"Jpn J Radiol"},{"issue":"10","key":"1892_CR42","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00262-020-02682-w","volume":"69","author":"S Ravaioli","year":"2020","unstructured":"Ravaioli S, Limarzi F, Tumedei MM, Palleschi M, Maltoni R, Bravaccini S. Are we ready to use TMB in breast cancer clinical practice? Cancer Immunol Immunother. 2020;69(10):1943\u20135. https:\/\/doi.org\/10.1007\/s00262-020-02682-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1892_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-020-00188-2","volume":"8","author":"Y Wu","year":"2020","unstructured":"Wu Y, Xu J, Xu J, Wang Y, Wang L, Lv W, et al. The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients\u2019 age. Biomark Res. 2020;8(1):9. https:\/\/doi.org\/10.1186\/s40364-020-00188-2.","journal-title":"Biomark Res"},{"issue":"10","key":"1892_CR44","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1002\/ijc.32327","volume":"145","author":"S Wang","year":"2019","unstructured":"Wang S, Zhang J, He Z, Wu K, Liu X. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients\u2019 sex. Int J Cancer. 2019;145(10):2840\u20139. https:\/\/doi.org\/10.1002\/ijc.32327.","journal-title":"Int J Cancer"},{"key":"1892_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.706652\/full","author":"T Huang","year":"2021","unstructured":"Huang T, Chen X, Zhang H, Liang Y, Li L, Wei H, et al. Prognostic role of tumor mutational burden in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.706652\/full.","journal-title":"Front Oncol"},{"issue":"15","key":"1892_CR46","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.3390\/cancers15153997","volume":"15","author":"R Barroso-Sousa","year":"2023","unstructured":"Barroso-Sousa R. Tumor mutational burden in breast cancer: current evidence, challenges, and opportunities. Cancers (Basel). 2023;15(15):3997.","journal-title":"Cancers (Basel)"},{"key":"1892_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/EDBK_351186","volume":"42","author":"J Dixon-Douglas","year":"2022","unstructured":"Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S. Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer. Am Soc Clin Oncol Educ B. 2022;42:47\u201359. https:\/\/doi.org\/10.1200\/EDBK_351186.","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"3","key":"1892_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607\u201317. https:\/\/doi.org\/10.1007\/s00262-020-02736-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"1892_CR49","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1158\/1078-0432.CCR-20-0458","volume":"26","author":"A Osipov","year":"2020","unstructured":"Osipov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L, et al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis. Clin Cancer Res. 2020;26(18):4842\u201351.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1892_CR50","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","volume":"26","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, et al. Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1\/L1 blockade in metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26(11):2565\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3507.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1892_CR51","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41392-023-01672-5","volume":"8","author":"Y Han","year":"2023","unstructured":"Han Y, Wang J, Sun T, Ouyang Q, Li J, Yuan J, et al. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer. Signal Transduct Target Ther. 2023;8(1):429.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1892_CR52","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s11864-023-01087-y","volume":"24","author":"J Dixon-Douglas","year":"2023","unstructured":"Dixon-Douglas J, Loi S. Immunotherapy in early-stage triple-negative breast cancer: where are we now and where are we headed? Curr Treat Options Oncol. 2023;24(8):1004\u201320.","journal-title":"Curr Treat Options Oncol"},{"key":"1892_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.779786\/full","author":"Q Tan","year":"2022","unstructured":"Tan Q, Yin S, Zhou D, Chi Y, Man X, Li H. Potential predictive and prognostic value of biomarkers related to immune checkpoint inhibitor therapy of triple-negative breast cancer. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.779786\/full.","journal-title":"Front Oncol"},{"key":"1892_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.878658\/full","author":"W Yang","year":"2022","unstructured":"Yang W, Qiu Z, Zhang J, Zhi X, Yang L, Qiu M, et al. Correlation between immune cell infiltration and PD-L1 expression and immune-related lncRNA determination in triple-negative breast cancer. Front Genet. 2022. https:\/\/doi.org\/10.3389\/fgene.2022.878658\/full.","journal-title":"Front Genet"},{"key":"1892_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571545","author":"Y Gao","year":"2020","unstructured":"Gao Y, Yang C, He N, Zhao G, Wang J, Yang Y. Integration of the tumor mutational burden and tumor heterogeneity identify an immunological subtype of melanoma with favorable survival. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.571545.","journal-title":"Front Oncol"},{"issue":"6","key":"1892_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1634\/theoncologist.2019-0611","volume":"25","author":"F Loupakis","year":"2020","unstructured":"Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, et al. Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. Oncologist. 2020;25(6):481\u20137.","journal-title":"Oncologist"},{"issue":"1","key":"1892_CR57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12885-024-11852-3","volume":"24","author":"N Yan","year":"2024","unstructured":"Yan N, Zhang H, Shen S, Guo S, Li X. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data. BMC Cancer. 2024;24(1):178. https:\/\/doi.org\/10.1186\/s12885-024-11852-3.","journal-title":"BMC Cancer"},{"key":"1892_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634841\/full","author":"W Xue","year":"2021","unstructured":"Xue W, Wang Y, Xie Y, Yang C, Gong Z, Guan C, et al. miRNA-based signature associated with tumor mutational burden in colon adenocarcinoma. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.634841\/full.","journal-title":"Front Oncol"},{"key":"1892_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00171","volume":"3","author":"NI Vokes","year":"2019","unstructured":"Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis Oncol. 2019;3:1\u201312. https:\/\/doi.org\/10.1200\/PO.19.00171.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"1892_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","volume":"11","author":"Z Liu","year":"2018","unstructured":"Liu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol. 2018;11(2):311\u201329.","journal-title":"Transl Oncol"},{"issue":"1","key":"1892_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","volume":"17","author":"Y Shi","year":"2018","unstructured":"Shi Y, Jin J, Ji W, Guan X. Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer. 2018;17(1):99. https:\/\/doi.org\/10.1186\/s12943-018-0850-9.","journal-title":"Mol Cancer"},{"issue":"7","key":"1892_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004825","volume":"10","author":"JD Park","year":"2022","unstructured":"Park JD, Kim KS, Choi SH, Jo GH, Choi JH, Park SW, et al. ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. J Immunother Cancer. 2022;10(7):e004825. https:\/\/doi.org\/10.1136\/jitc-2022-004825.","journal-title":"J Immunother Cancer"},{"key":"1892_CR63","doi-asserted-by":"publisher","first-page":"903065","DOI":"10.3389\/fmolb.2022.903065","volume":"9","author":"R Ribeiro","year":"2022","unstructured":"Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci. 2022;9:903065.","journal-title":"Front Mol Biosci"},{"key":"1892_CR64","doi-asserted-by":"publisher","first-page":"1095839","DOI":"10.3389\/fgene.2022.1095839","volume":"13","author":"S Loizides","year":"2023","unstructured":"Loizides S, Constantinidou A. Triple negative breast cancer: immunogenicity, tumor microenvironment, and immunotherapy. Front Genet. 2023;13:1095839.","journal-title":"Front Genet"},{"issue":"10","key":"1892_CR65","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PAI.0000000000001231","volume":"32","author":"P Gupta","year":"2024","unstructured":"Gupta P, Thakur T, Chadda A, Irinike S, Khare S, Bal A. A pilot study on BRCA1\/2 and PI3K mutations across subtypes of triple negative breast cancer in North Indian population. Appl Immunohistochem Mol Morphol. 2024;32(10):462\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"1892_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141763","volume":"10","author":"P Cossu-Rocca","year":"2015","unstructured":"Cossu-Rocca P, Orr\u00f9 S, Muroni MR, Sanges F, Sotgiu G, Ena S, et al. Analysis of PIK3CA mutations and activation pathways in triple negative breast cancer. PLoS ONE. 2015;10(11):e0141763. https:\/\/doi.org\/10.1371\/journal.pone.0141763.","journal-title":"PLoS ONE"},{"key":"1892_CR67","doi-asserted-by":"publisher","first-page":"650491","DOI":"10.3389\/fimmu.2021.650491","volume":"12","author":"C Gao","year":"2021","unstructured":"Gao C, Li H, Liu C, Xu X, Zhuang J, Zhou C, et al. Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: genome high-throughput data analysis. Front Immunol. 2021;12:650491.","journal-title":"Front Immunol"},{"issue":"7","key":"1892_CR68","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750\u201367.","journal-title":"J Clin Investig"},{"issue":"15_suppl","key":"1892_CR69","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/jco.2013.31.15_suppl.1005","volume":"31","author":"H Masuda","year":"2013","unstructured":"Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. J Clin Oncol. 2013;31(15_suppl):1005\u20131005.","journal-title":"J Clin Oncol"},{"key":"1892_CR70","doi-asserted-by":"crossref","unstructured":"Lehmann BD, Jovanovi\u0107 B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection; 2016. [cited 2023 Nov 30]","DOI":"10.1371\/journal.pone.0157368"},{"key":"1892_CR71","doi-asserted-by":"crossref","unstructured":"Qayoom H, Mehraj U, Aisha S, Sofi S, Ahmad Mir M. Integrating immunotherapy with chemotherapy: a new approach to drug repurposing. In: Drug repurposing - molecular aspects and therapeutic applications [Internet]. IntechOpen; 2022. Available from: https:\/\/www.intechopen.com\/chapters\/78716.","DOI":"10.5772\/intechopen.100183"},{"issue":"19","key":"1892_CR72","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.3390\/cancers15194879","volume":"15","author":"K Das","year":"2023","unstructured":"Das K, Paul S, Ghosh A, Gupta S, Mukherjee T, Shankar P, et al. Extracellular vesicles in triple-negative breast cancer: immune regulation, biomarkers, and immunotherapeutic potential. Cancers (Basel). 2023;15(19):4879.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1892_CR73","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12282-021-01247-8","volume":"28","author":"J Zhang","year":"2021","unstructured":"Zhang J, Tian Q, Zhang M, Wang H, Wu L, Yang J. Immune-related biomarkers in triple-negative breast cancer. Breast Cancer. 2021;28(4):792\u2013805. https:\/\/doi.org\/10.1007\/s12282-021-01247-8.","journal-title":"Breast Cancer"},{"issue":"2","key":"1892_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/23808993.2020.1730694","volume":"5","author":"JA Kagihara","year":"2020","unstructured":"Kagihara JA, Andress M, Diamond JR. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Rev Precis Med Drug Dev. 2020;5(2):59\u201365.","journal-title":"Expert Rev Precis Med Drug Dev"},{"issue":"2","key":"1892_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/ijo.2022.5385","volume":"61","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ge X, Jiang T, Yang R, Li S. Research progress on immunotherapy in triple-negative breast cancer (review). Int J Oncol. 2022;61(2):95. https:\/\/doi.org\/10.3892\/ijo.2022.5385.","journal-title":"Int J Oncol"},{"key":"1892_CR76","doi-asserted-by":"publisher","first-page":"995555","DOI":"10.3389\/fphar.2022.995555","volume":"13","author":"Q Gou","year":"2022","unstructured":"Gou Q, Liu Z, Xie Y, Deng Y, Ma J, Li J, et al. Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. Front Pharmacol. 2022;13:995555.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1892_CR77","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","volume":"12","author":"R Bao","year":"2020","unstructured":"Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12(1):90. https:\/\/doi.org\/10.1186\/s13073-020-00787-6.","journal-title":"Genome Med"},{"key":"1892_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168\/full","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00168\/full.","journal-title":"Front Immunol"},{"key":"1892_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142862\/full","author":"G Zheng","year":"2023","unstructured":"Zheng G, Lu Y, Yang Z, Chen H, Liang Q, Zhu Q, et al. Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1142862\/full.","journal-title":"Front Immunol"},{"issue":"7559","key":"1892_CR80","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135.","journal-title":"Nature"},{"issue":"1","key":"1892_CR81","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12(1):5668.","journal-title":"Nat Commun"},{"issue":"1","key":"1892_CR82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327. https:\/\/doi.org\/10.1186\/s13046-018-1002-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1892_CR83","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/jitc-2019-000147","volume":"8","author":"DM Merino","year":"2020","unstructured":"Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):147.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1892_CR84","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):10232.","journal-title":"Nat Commun"},{"key":"1892_CR85","doi-asserted-by":"crossref","unstructured":"Mel\u00e9ndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D\u2019Haene N. Methods of measurement for tumor mutational burden in tumor tissue. Vol 7, Translational Lung Cancer Research. AME Publishing Company, pp 661\u2013667; 2018.","DOI":"10.21037\/tlcr.2018.08.02"},{"issue":"1","key":"1892_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2021.12816","volume":"22","author":"F Fenizia","year":"2021","unstructured":"Fenizia F, Pasquale R, Abate RE, Lambiase M, Roma C, Bergantino F, et al. Challenges in bioinformatics approaches to tumor mutation burden analysis. Oncol Lett. 2021;22(1):1\u20137. https:\/\/doi.org\/10.3892\/ol.2021.12816.","journal-title":"Oncol Lett"},{"issue":"6","key":"1892_CR87","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00428-021-03093-7","volume":"479","author":"F Fenizia","year":"2021","unstructured":"Fenizia F, Wolstenholme N, Fairley JA, Rouleau E, Cheetham MH, Horan MP, et al. Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path). Virchows Arch. 2021;479(6):1067\u201372. https:\/\/doi.org\/10.1007\/s00428-021-03093-7.","journal-title":"Virchows Arch"},{"issue":"12","key":"1892_CR88","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the friends of cancer research TMB harmonization project. Ann Oncol. 2021;32(12):1626\u201336.","journal-title":"Ann Oncol"},{"key":"1892_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4939-9773-2_3","volume-title":"Biomarkers for immunotherapy of cancer: methods and protocols","author":"T Vilimas","year":"2020","unstructured":"Vilimas T. Measuring tumor mutational burden using whole-exome sequencing. In: Thurin M, Cesano A, Marincola FM, editors. Biomarkers for immunotherapy of cancer: methods and protocols. New York: Springer; 2020. p. 63\u201391. https:\/\/doi.org\/10.1007\/978-1-4939-9773-2_3."},{"issue":"1","key":"1892_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2.","journal-title":"Genome Med"},{"issue":"1","key":"1892_CR91","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1038\/s41598-020-61575-1","volume":"10","author":"L Yao","year":"2020","unstructured":"Yao L, Fu Y, Mohiyuddin M, Lam HYK. ecTMB: a robust method to estimate and classify tumor mutational burden. Sci Rep. 2020;10(1):4983.","journal-title":"Sci Rep"},{"key":"1892_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1235902\/full","author":"S Sammons","year":"2023","unstructured":"Sammons S, Elliott A, Barroso-Sousa R, Chumsri S, Tan AR, Sledge GW, et al. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1235902\/full.","journal-title":"Front Oncol"},{"key":"1892_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7384","author":"S Chen","year":"2024","unstructured":"Chen S, Tse K, Lu Y, Chen S, Tian Y, Tan KT, et al. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-na\u00efve breast cancer. Cancer Med. 2024. https:\/\/doi.org\/10.1002\/cam4.7384.","journal-title":"Cancer Med"},{"key":"1892_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.721505\/full","author":"X Jin","year":"2021","unstructured":"Jin X, Yan J, Chen C, Chen Y, Huang WK. Integrated analysis of copy number variation, microsatellite instability, and tumor mutation burden identifies an 11-gene signature predicting survival in breast cancer. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.721505\/full.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"1892_CR95","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1002\/cam4.2381","volume":"8","author":"Y Zang","year":"2019","unstructured":"Zang Y, Dai C, Xu X, Cai X, Wang G, Wei J, et al. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. 2019;8(10):4699\u2013708. https:\/\/doi.org\/10.1002\/cam4.2381.","journal-title":"Cancer Med"},{"issue":"1","key":"1892_CR96","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-015-0301-9","volume":"14","author":"YY Chang","year":"2015","unstructured":"Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, et al. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer. 2015;14(1):36. https:\/\/doi.org\/10.1186\/s12943-015-0301-9.","journal-title":"Mol Cancer"},{"key":"1892_CR97","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/jcm11061605","volume":"11","author":"IA Voutsadakis","year":"2022","unstructured":"Voutsadakis IA. High mutation burden in ER-Positive\/HER2-Negative\/Luminal breast cancers. J Clin Med. 2022;11:1605.","journal-title":"J Clin Med"},{"issue":"2","key":"1892_CR98","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373.","journal-title":"Cancer Cell"},{"key":"1892_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8836493","volume":"2020","author":"J Lin","year":"2020","unstructured":"Lin J, Lin Y, Huang Z, Li X. Identification of prognostic biomarkers of cutaneous melanoma based on analysis of tumor mutation burden. Comput Math Methods Med. 2020;2020:1\u201314.","journal-title":"Comput Math Methods Med"},{"issue":"40","key":"1892_CR100","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.18632\/oncotarget.26998","volume":"10","author":"C Ang","year":"2019","unstructured":"Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019;10(40):4018\u201325.","journal-title":"Oncotarget"},{"key":"1892_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8072796","volume":"2021","author":"Z Xu","year":"2021","unstructured":"Xu Z, Xiang L, Wang R, Xiong Y, Zhou H, Gu H, et al. Bioinformatic analysis of immune significance of RYR2 mutation in breast cancer. Biomed Res Int. 2021;2021:1\u201312.","journal-title":"Biomed Res Int"},{"key":"1892_CR102","volume":"30","author":"DJ Craig","year":"2022","unstructured":"Craig DJ, Bailey MM, Noe OB, Williams KK, Stanbery L, Hamouda DM, et al. Subclonal landscape of cancer drives resistance to immune therapy. Cancer Treat Res Commun. 2022;30:100507.","journal-title":"Cancer Treat Res Commun"},{"issue":"7","key":"1892_CR103","doi-asserted-by":"publisher","first-page":"551","DOI":"10.21037\/atm-20-6049","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang J, An L, Zhou X, Shi R, Wang H. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. Ann Transl Med. 2021;9(7):551\u2013551.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1892_CR104","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/genes13030432","volume":"13","author":"NG Bailey","year":"2022","unstructured":"Bailey NG. Visualization of the effect of assay size on the error profile of tumor mutational burden measurement. Genes (Basel). 2022;13(3):432.","journal-title":"Genes (Basel)"},{"issue":"1","key":"1892_CR105","doi-asserted-by":"publisher","first-page":"351","DOI":"10.18632\/aging.104204","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Zhang X, Li J, Ma X, Feng F, Liu L, et al. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration. Aging (Albany NY). 2021;13(1):351\u201363. https:\/\/doi.org\/10.18632\/aging.104204.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"1892_CR106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. https:\/\/doi.org\/10.1186\/s13045-019-0787-5.","journal-title":"J Hematol Oncol"},{"key":"1892_CR107","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166740","author":"E Kina","year":"2024","unstructured":"Kina E, Laverdure JP, Durette C, Lanoix J, Courcelles M, Zhao Q, et al. Breast cancer immunopeptidomes contain numerous shared tumor antigens. J Clin Investig. 2024. https:\/\/doi.org\/10.1172\/JCI166740.","journal-title":"J Clin Investig"},{"key":"1892_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109542","volume":"120","author":"X Zhang","year":"2019","unstructured":"Zhang X, Qi Y, Zhang Q, Liu W. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy. Biomed Pharmacother. 2019;120:109542.","journal-title":"Biomed Pharmacother"},{"key":"1892_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201700465","author":"N Ternette","year":"2018","unstructured":"Ternette N, Olde Nordkamp MJM, M\u00fcller J, Anderson AP, Nicastri A, Hill AVS, et al. Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics. 2018. https:\/\/doi.org\/10.1002\/pmic.201700465.","journal-title":"Proteomics"},{"key":"1892_CR110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/apc-2023-1","volume":"6","author":"Y Shao","year":"2023","unstructured":"Shao Y, Zhang T, Celiker B, Fujiwara K. Direct identification of T cell epitopes in cancer tissues. Ann Pancreat Cancer. 2023;6:3\u20133.","journal-title":"Ann Pancreat Cancer"},{"key":"1892_CR111","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2404665","author":"S Matsumoto","year":"2024","unstructured":"Matsumoto S, Tsujikawa T, Tokita S, Mohamed Bedeir M, Matsuo K, Hata F, et al. HLA class II neoantigen presentation for CD4 + T cell surveillance in HLA class II-negative colorectal cancer. Oncoimmunology. 2024. https:\/\/doi.org\/10.1080\/2162402X.2024.2404665.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1892_CR112","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic cells revisited. Annu Rev Immunol. 2021;39(1):131\u201366. https:\/\/doi.org\/10.1146\/annurev-immunol-061020-053707.","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"1892_CR113","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-19-3517","volume":"26","author":"M Kloor","year":"2020","unstructured":"Kloor M, Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Al-Batran SE, et al. A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I\/IIa clinical trial. Clin Cancer Res. 2020;26(17):4503\u201310.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1892_CR114","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/cas.15291","volume":"113","author":"J Charneau","year":"2022","unstructured":"Charneau J, Suzuki T, Shimomura M, Fujinami N, Mishima Y, Hiranuka K, et al. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci. 2022;113(4):1113\u201324. https:\/\/doi.org\/10.1111\/cas.15291.","journal-title":"Cancer Sci"},{"issue":"7","key":"1892_CR115","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/pharmaceutics14071515","volume":"14","author":"LT Oosting","year":"2022","unstructured":"Oosting LT, Franke K, Martin MV, Kloosterman WP, Jamieson JA, Glenn LA, et al. Development of a personalized tumor neoantigen based vaccine formulation (FRAME-001) for use in a phase II trial for the treatment of advanced non-small cell lung cancer. Pharmaceutics. 2022;14(7):1515.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1892_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00849-0","volume":"30","author":"Y Sun","year":"2024","unstructured":"Sun Y, Xiong B, Shuai X, Li J, Wang C, Guo J, et al. Downregulation of HNRNPA1 induced neoantigen generation via regulating alternative splicing. Mol Med. 2024;30(1):85. https:\/\/doi.org\/10.1186\/s10020-024-00849-0.","journal-title":"Mol Med"},{"issue":"1","key":"1892_CR117","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","volume":"6","author":"Z Guo","year":"2022","unstructured":"Guo Z, Yuan Y, Chen C, Lin J, Ma Q, Liu G, et al. Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. Npj Precis Oncol. 2022;6(1):34.","journal-title":"Npj Precis Oncol"},{"key":"1892_CR118","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gore.2016.12.009","volume":"19","author":"SA Shukla","year":"2017","unstructured":"Shukla SA, Howitt BE, Wu CJ, Konstantinopoulos PA. Predicted neoantigen load in non-hypermutated endometrial cancers: correlation with outcome and tumor-specific genomic alterations. Gynecol Oncol Rep. 2017;19:42\u20135.","journal-title":"Gynecol Oncol Rep"},{"key":"1892_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682325\/full","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Liu J. The role of neoantigens in cancer immunotherapy. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.682325\/full.","journal-title":"Front Oncol"},{"issue":"1","key":"1892_CR120","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10585-021-10092-0","volume":"39","author":"AS Blucher","year":"2022","unstructured":"Blucher AS, Mills GB, Tsang YH. Precision oncology for breast cancer through clinical trials. Clin Exp Metastasis. 2022;39(1):71\u20138. https:\/\/doi.org\/10.1007\/s10585-021-10092-0.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"1892_CR121","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11427-020-1714-8","volume":"64","author":"SY Wu","year":"2021","unstructured":"Wu SY, Wang H, Shao ZM, Jiang YZ. Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Sci China Life Sci. 2021;64(3):372\u201388. https:\/\/doi.org\/10.1007\/s11427-020-1714-8.","journal-title":"Sci China Life Sci"},{"key":"1892_CR122","doi-asserted-by":"crossref","unstructured":"Natesh J, Penta D, Meeran SM (2022) Chapter 3. Epigenetics in precision medicine of breast cancer. In: Garc\u00eda-Gim\u00e9nez JL (ed) Epigenetics in precision medicine. Academic Press, pp 43\u201367. (Translational Epigenetics; vol 30)","DOI":"10.1016\/B978-0-12-823008-4.00004-4"},{"issue":"1","key":"1892_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82418-7","volume":"11","author":"M Kenn","year":"2021","unstructured":"Kenn M, Cacsire Castillo-Tong D, Singer CF, Karch R, Cibena M, Koelbl H, et al. Decision theory for precision therapy of breast cancer. Sci Rep. 2021;11(1):4233.","journal-title":"Sci Rep"},{"issue":"2","key":"1892_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188521","volume":"1875","author":"J Jin","year":"2021","unstructured":"Jin J, Tao Z, Cao J, Li T, Hu X. DNA damage response inhibitors: an avenue for TNBC treatment. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188521.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1892_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731535","author":"Y Li","year":"2021","unstructured":"Li Y, Zhan Z, Yin X, Fu S, Deng X. Targeted therapeutic strategies for triple-negative breast cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.731535.","journal-title":"Front Oncol"},{"issue":"4","key":"1892_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040916","volume":"12","author":"E Vagia","year":"2020","unstructured":"Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. Cancers (Basel). 2020;12(4):916.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"1892_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153739","volume":"13","author":"F Hossain","year":"2021","unstructured":"Hossain F, Majumder S, David J, Miele L. Precision medicine and triple-negative breast cancer: current landscape and future directions. Cancers (Basel). 2021;13(15):3739.","journal-title":"Cancers (Basel)"},{"key":"1892_CR128","doi-asserted-by":"publisher","first-page":"120835","DOI":"10.1016\/j.ijpharm.2021.120835","volume":"605","author":"R Chadar","year":"2021","unstructured":"Chadar R, Afsana, Kesharwani P. Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer. Int J Pharm. 2021;605:120835.","journal-title":"Int J Pharm"},{"issue":"6","key":"1892_CR129","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14656566.2020.1724957","volume":"21","author":"G Garufi","year":"2020","unstructured":"Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, et al. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother. 2020;21(6):687\u201399.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"1892_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082204","volume":"15","author":"MA Subhan","year":"2023","unstructured":"Subhan MA, Parveen F, Shah H, Yalamarty SSK, Ataide JA, Torchilin VP. Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type. Cancers (Basel). 2023;15(8):2204.","journal-title":"Cancers (Basel)"},{"issue":"24","key":"1892_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/cells13242126","volume":"13","author":"S Khan","year":"2024","unstructured":"Khan S, Jandrajupalli SB, Bushara NZA, Raja RDP, Mirza S, Sharma K, et al. Targeting refractory triple-negative breast cancer with Sacituzumab Govitecan: a new era in precision medicine. Cells. 2024;13(24):2126.","journal-title":"Cells"},{"issue":"10","key":"1892_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ph14101008","volume":"14","author":"WJ Ryu","year":"2021","unstructured":"Ryu WJ, Sohn JH. Molecular targets and promising therapeutics of triple-negative breast cancer. Pharmaceuticals. 2021;14(10):1008.","journal-title":"Pharmaceuticals"},{"key":"1892_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000357","volume":"3","author":"JH Park","year":"2018","unstructured":"Park JH, Ahn JH, Kim SB. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open. 2018;3:e000357.","journal-title":"ESMO Open"},{"issue":"13","key":"1892_CR134","doi-asserted-by":"publisher","first-page":"1119611","DOI":"10.3389\/fonc.2023.1119611","volume":"16","author":"SL Cai","year":"2023","unstructured":"Cai SL, Liu JJ, Liu YX, Yu SH, Liu X, Lin XQ, et al. Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. Front Oncol. 2023;16(13):1119611.","journal-title":"Front Oncol"},{"issue":"1","key":"1892_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020;22(1):120.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"1892_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105207","volume":"22","author":"C Yan","year":"2021","unstructured":"Yan C, Yang J, Saleh N, Chen SC, Ayers GD, Abramson VG, et al. Inhibition of the PI3K\/mTOR pathway in breast cancer to enhance response to immune checkpoint inhibitors in breast cancer. Int J Mol Sci. 2021;22(10):5207.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1892_CR137","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1038\/s41467-023-40841-6","volume":"14","author":"ZO Doha","year":"2023","unstructured":"Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, et al. MYC deregulation and PTEN loss model tumor and stromal heterogeneity of aggressive triple-negative breast cancer. Nat Commun. 2023;14(1):5665.","journal-title":"Nat Commun"},{"key":"1892_CR138","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231189422","author":"H Chen","year":"2023","unstructured":"Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, et al. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023. https:\/\/doi.org\/10.1177\/17588359231189422.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"1892_CR139","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","volume":"31","author":"H Zhang","year":"2024","unstructured":"Zhang H, Jiang R, Zhu J, Sun K, Huang Y, Zhou H, et al. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539\u201351. https:\/\/doi.org\/10.1007\/s12282-024-01567-5.","journal-title":"Breast Cancer"},{"key":"1892_CR140","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jss.2017.09.035","volume":"222","author":"W Zhang","year":"2018","unstructured":"Zhang W, Wang X, Gao S, Chen C, Xu X, Sun Q, et al. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res. 2018;222:93\u2013101.","journal-title":"J Surg Res"},{"key":"1892_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"LQ Fu","year":"2020","unstructured":"Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119.","journal-title":"Cell Immunol"},{"issue":"1","key":"1892_CR142","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-022-06609-0","volume":"194","author":"A Giatromanolaki","year":"2022","unstructured":"Giatromanolaki A, Gkegka AG, Pouliliou S, Biziota E, Kakolyris S, Koukourakis M. Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis. Breast Cancer Res Treat. 2022;194(1):13\u201323. https:\/\/doi.org\/10.1007\/s10549-022-06609-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1892_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01453-1","volume":"16","author":"L Yang","year":"2023","unstructured":"Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. J Hematol Oncol. 2023;16(1):59. https:\/\/doi.org\/10.1186\/s13045-023-01453-1.","journal-title":"J Hematol Oncol"},{"key":"1892_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982821\/full","author":"M Hasmim","year":"2022","unstructured":"Hasmim M, Xiao M, Van Moer K, Kumar A, Oniga A, Mittelbronn M, et al. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.982821\/full.","journal-title":"Front Immunol"},{"key":"1892_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.563044","author":"X Xie","year":"2020","unstructured":"Xie X, Zhang J, Shi Z, Liu W, Hu X, Qie C, et al. The expression pattern and clinical significance of the immune checkpoint regulator VISTA in human breast cancer. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.563044.","journal-title":"Front Immunol"},{"issue":"1","key":"1892_CR146","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/s41467-019-10424-5","volume":"10","author":"L Racioppi","year":"2019","unstructured":"Racioppi L, Nelson ER, Huang W, Mukherjee D, Lawrence SA, Lento W, et al. CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. Nat Commun. 2019;10(1):2450.","journal-title":"Nat Commun"},{"issue":"7","key":"1892_CR147","doi-asserted-by":"publisher","first-page":"11768","DOI":"10.1002\/jcp.27839","volume":"234","author":"LD Naorem","year":"2019","unstructured":"Naorem LD, Muthaiyan M, Venkatesan A. Identification of dysregulated miRNAs in triple negative breast cancer: a meta-analysis approach. J Cell Physiol. 2019;234(7):11768\u201379. https:\/\/doi.org\/10.1002\/jcp.27839.","journal-title":"J Cell Physiol"},{"key":"1892_CR148","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6319","author":"L Xu","year":"2018","unstructured":"Xu L, Che X, Wu Y, Song N, Shi S, Wang S, et al. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Rep. 2018. https:\/\/doi.org\/10.3892\/or.2018.6319.","journal-title":"Oncol Rep"},{"issue":"1","key":"1892_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80081-y","volume":"11","author":"K Anand","year":"2021","unstructured":"Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, et al. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep. 2021;11(1):82.","journal-title":"Sci Rep"},{"issue":"2","key":"1892_CR150","doi-asserted-by":"publisher","first-page":"e0210891","DOI":"10.1371\/journal.pone.0210891","volume":"14","author":"C Murphy","year":"2019","unstructured":"Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, et al. Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: the phase II NEONAB trial\u2014clinical outcomes and molecular determinants of response. PLoS ONE. 2019;14(2):e0210891. https:\/\/doi.org\/10.1371\/journal.pone.0210891.","journal-title":"PLoS ONE"},{"key":"1892_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291643\/full","author":"MR Moamin","year":"2023","unstructured":"Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A, et al. Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1291643\/full.","journal-title":"Front Immunol"},{"key":"1892_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1441820\/full","author":"M Stavrou","year":"2024","unstructured":"Stavrou M, Constantinidou A. Tumor associated macrophages in breast cancer progression: implications and clinical relevance. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1441820\/full.","journal-title":"Front Immunol"},{"issue":"11","key":"1892_CR153","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/eji.202149379","volume":"51","author":"C Belgiovine","year":"2021","unstructured":"Belgiovine C, Frapolli R, Liguori M, Digifico E, Colombo FS, Meroni M, et al. Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy. Eur J Immunol. 2021;51(11):2677\u201386. https:\/\/doi.org\/10.1002\/eji.202149379.","journal-title":"Eur J Immunol"},{"issue":"18","key":"1892_CR154","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.3390\/ijms21186742","volume":"21","author":"MM Krebber","year":"2020","unstructured":"Krebber MM, van Dijk CGM, Vernooij RWM, Brandt MM, Emter CA, Rau CD, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in extracellular matrix remodeling during left ventricular diastolic dysfunction and heart failure with preserved ejection fraction: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(18):6742.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1892_CR155","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-19-1945","volume":"26","author":"K Asleh","year":"2020","unstructured":"Asleh K, Brauer HA, Sullivan A, Lauttia S, Lindman H, Nielsen TO, et al. Predictive biomarkers for adjuvant capecitabine benefit in early-stage triple-negative breast cancer in the FinXX clinical trial. Clin Cancer Res. 2020;26(11):2603\u201314.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1892_CR156","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13054-016-1555-3","volume":"20","author":"J Ho","year":"2016","unstructured":"Ho J, Chan H, Wong SH, Wang MHT, Yu J, Xiao Z, et al. The involvement of regulatory non-coding RNAs in sepsis: a systematic review. Crit Care. 2016;20(1):383. https:\/\/doi.org\/10.1186\/s13054-016-1555-3.","journal-title":"Crit Care"},{"issue":"1","key":"1892_CR157","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1038\/s41467-021-25769-z","volume":"12","author":"TE Keenan","year":"2021","unstructured":"Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O\u2019Meara T, Giobbie-Hurder A, et al. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021;12(1):5563.","journal-title":"Nat Commun"},{"issue":"1","key":"1892_CR158","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13073-020-00729-2","volume":"12","author":"MA Wood","year":"2020","unstructured":"Wood MA, Weeder BR, David JK, Nellore A, Thompson RF. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Med. 2020;12(1):33.","journal-title":"Genome Med"},{"key":"1892_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103137","volume":"63","author":"Y Zou","year":"2021","unstructured":"Zou Y, Hu X, Zheng S, Yang A, Li X, Tang H, et al. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: a systematic review and meta-analysis. EBioMedicine. 2021;63:103137.","journal-title":"EBioMedicine"},{"issue":"2","key":"1892_CR160","doi-asserted-by":"publisher","first-page":"030006052199101","DOI":"10.1177\/0300060521991019","volume":"49","author":"Z Chen","year":"2021","unstructured":"Chen Z, Wang X, Li X, Zhou Y, Chen K. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. J Int Med Res. 2021;49(2):030006052199101.","journal-title":"J Int Med Res"},{"key":"1892_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00909\/full","author":"H Chen","year":"2018","unstructured":"Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, et al. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00909\/full.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1892_CR162","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1634\/theoncologist.2019-0321","volume":"24","author":"S Chia","year":"2019","unstructured":"Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, et al. A phase Ib trial of durvalumab in combination with trastuzumab in HER2-positive metastatic breast cancer (CCTG IND.229). Oncologist. 2019;24(11):1439\u201345.","journal-title":"Oncologist"},{"issue":"7","key":"1892_CR163","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1021\/acs.nanolett.0c00953","volume":"20","author":"J Bu","year":"2020","unstructured":"Bu J, Nair A, Iida M, Jeong JW, Poellmann MJ, Mudd K, et al. An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett. 2020;20(7):4901\u20139.","journal-title":"Nano Lett"},{"issue":"1","key":"1892_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4(1):59.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1892_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076420","volume":"24","author":"D Alkaabi","year":"2023","unstructured":"Alkaabi D, Arafat K, Sulaiman S, Al-Azawi AM, Attoub S. PD-1 independent role of PD-L1 in triple-negative breast cancer progression. Int J Mol Sci. 2023;24(7):6420.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1892_CR166","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","volume":"26","author":"B Sidders","year":"2020","unstructured":"Sidders B, Zhang P, Goodwin K, O\u2019Connor G, Russell DL, Borodovsky A, et al. Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response. Clin Cancer Res. 2020;26(9):2176\u201387.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1892_CR167","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13058-020-01297-4","volume":"22","author":"Y Abdou","year":"2020","unstructured":"Abdou Y, Attwood K, Cheng TYD, Yao S, Bandera EV, Zirpoli GR, et al. Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women. Breast Cancer Res. 2020;22(1):62.","journal-title":"Breast Cancer Res"},{"issue":"16","key":"1892_CR168","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/0008-5472.CAN-19-0617","volume":"79","author":"VM Ngwa","year":"2019","unstructured":"Ngwa VM, Edwards DN, Philip M, Chen J. Microenvironmental metabolism regulates antitumor immunity. Cancer Res. 2019;79(16):4003\u20138.","journal-title":"Cancer Res"},{"issue":"10","key":"1892_CR169","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1021\/acs.jproteome.8b00636","volume":"17","author":"CC Going","year":"2018","unstructured":"Going CC, Tailor D, Kumar V, Birk AM, Pandrala M, Rice MA, et al. Quantitative proteomic profiling reveals key pathways in the anticancer action of methoxychalcone derivatives in triple negative breast cancer. J Proteome Res. 2018;17(10):3574\u201385.","journal-title":"J Proteome Res"},{"issue":"1","key":"1892_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00714-6","volume":"12","author":"Z Guo","year":"2024","unstructured":"Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L, et al. Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomark Res. 2024;12(1):166. https:\/\/doi.org\/10.1186\/s40364-024-00714-6.","journal-title":"Biomark Res"},{"issue":"7","key":"1892_CR171","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006097","volume":"96","author":"L Zhan","year":"2017","unstructured":"Zhan L, Zhang B, Tan Y, Yang C, Huang C, Wu Q, et al. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA). Medicine (Baltimore). 2017;96(7):e6097.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1892_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/srep17869","volume":"5","author":"L Zhang","year":"2015","unstructured":"Zhang L, Long X. Association of BRCA1 promoter methylation with sporadic breast cancers: evidence from 40 studies. Sci Rep. 2015;5(1):17869.","journal-title":"Sci Rep"},{"issue":"1","key":"1892_CR173","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-3544-6","volume":"18","author":"J Nemet","year":"2017","unstructured":"Nemet J, Vidan N, Sopta M. A meta-analysis reveals complex regulatory properties at Taf14-repressed genes. BMC Genomics. 2017;18(1):175.","journal-title":"BMC Genomics"},{"issue":"7","key":"1892_CR174","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/1759-7714.12647","volume":"9","author":"S Li","year":"2018","unstructured":"Li S, Shen L, Chen K. Association between H3K4 methylation and cancer prognosis: a meta-analysis. Thorac Cancer. 2018;9(7):794\u20139.","journal-title":"Thorac Cancer"},{"key":"1892_CR175","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3389\/fimmu.2019.00856","volume":"10","author":"Q Deng","year":"2019","unstructured":"Deng Q, Luo Y, Chang C, Wu H, Ding Y, Xiao R. The emerging epigenetic role of CD8+T cells in autoimmune diseases: a systematic review. Front Immunol. 2019;10:856.","journal-title":"Front Immunol"},{"issue":"4","key":"1892_CR176","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4049\/jimmunol.2300475","volume":"212","author":"ML Ibrahim","year":"2024","unstructured":"Ibrahim ML, Zheng H, Barlow ML, Latif Y, Chen Z, Yu X, et al. Histone deacetylase inhibitors directly modulate T cell gene expression and signaling and promote development of effector-exhausted T cells in murine tumors. J Immunol. 2024;212(4):737\u201347.","journal-title":"J Immunol"},{"issue":"69","key":"1892_CR177","doi-asserted-by":"publisher","first-page":"114156","DOI":"10.18632\/oncotarget.23169","volume":"8","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017;8(69):114156\u201372. https:\/\/doi.org\/10.18632\/oncotarget.23169.","journal-title":"Oncotarget"},{"issue":"3","key":"1892_CR178","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","volume":"38","author":"Y Qin","year":"2019","unstructured":"Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2019;38(3):390\u2013405.","journal-title":"Oncogene"},{"issue":"1","key":"1892_CR179","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","volume":"20","author":"G Gao","year":"2020","unstructured":"Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):179.","journal-title":"BMC Cancer"},{"issue":"6","key":"1892_CR180","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00262-020-02807-1","volume":"70","author":"H Zhang","year":"2021","unstructured":"Zhang H, Qin G, Yu H, Han X, Zhu S. Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(6):1649\u201365. https:\/\/doi.org\/10.1007\/s00262-020-02807-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1892_CR181","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/annonc\/mdx691","volume":"29","author":"C Criscitiello","year":"2018","unstructured":"Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, et al. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol. 2018;29(1):162\u20139.","journal-title":"Ann Oncol"},{"key":"1892_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668464","author":"AM Grimaldi","year":"2021","unstructured":"Grimaldi AM, Salvatore M, Incoronato M. MiRNA-based therapeutics in breast cancer: a systematic review. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.668464.","journal-title":"Front Oncol"},{"issue":"22","key":"1892_CR183","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007085","volume":"96","author":"L L\u00fc","year":"2017","unstructured":"L\u00fc L, Mao X, Shi P, He B, Xu K, Zhang S, et al. Micrornas in the prognosis of triple-negative breast cancer. Medicine (Baltimore). 2017;96(22):e7085.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"1892_CR184","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.3390\/nu13082821","volume":"13","author":"L Rasmussen","year":"2021","unstructured":"Rasmussen L, Knorr S, Antoniussen CS, Bruun JM, Ovesen PG, Fuglsang J, et al. The impact of lifestyle, diet and physical activity on epigenetic changes in the offspring\u2014a systematic review. Nutrients. 2021;13(8):2821.","journal-title":"Nutrients"},{"issue":"2","key":"1892_CR185","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26020273","volume":"26","author":"R Fabiani","year":"2021","unstructured":"Fabiani R, Vella N, Rosignoli P. Epigenetic modifications induced by olive oil and its phenolic compounds: a systematic review. Molecules. 2021;26(2):273.","journal-title":"Molecules"},{"issue":"6\u20137","key":"1892_CR186","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/15592294.2020.1712814","volume":"15","author":"S Bannister","year":"2020","unstructured":"Bannister S, Messina NL, Novakovic B, Curtis N. The emerging role of epigenetics in the immune response to vaccination and infection: a systematic review. Epigenetics. 2020;15(6\u20137):555\u201393.","journal-title":"Epigenetics"},{"key":"1892_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5463-1","author":"K Abdulrashid","year":"2019","unstructured":"Abdulrashid K, Alhussaini N, Ahmed W, Thalib L. Prevalence of BRCA mutations among hereditary breast and\/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/s12885-019-5463-1.","journal-title":"BMC Cancer"},{"key":"1892_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621639","author":"T Ouyang","year":"2021","unstructured":"Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, et al. Treatment-related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.621639.","journal-title":"Front Oncol"},{"issue":"12","key":"1892_CR189","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/gim.2016.29","volume":"18","author":"E D\u2019Andrea","year":"2016","unstructured":"D\u2019Andrea E, Marzuillo C, Vito C, Marco M, Pitini E. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med. 2016;18(12):1171\u201380. https:\/\/doi.org\/10.1038\/gim.2016.29.","journal-title":"Genet Med"},{"issue":"5","key":"1892_CR190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234058","volume":"15","author":"Y Ding","year":"2020","unstructured":"Ding Y, Ding K, Yang H, He X, Mo W, Ding X. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer? A meta-analysis of 3724 patients. PLoS ONE. 2020;15(5):e0234058. https:\/\/doi.org\/10.1371\/journal.pone.0234058.","journal-title":"PLoS ONE"},{"issue":"14","key":"1892_CR191","doi-asserted-by":"publisher","first-page":"23177","DOI":"10.18632\/oncotarget.15520","volume":"8","author":"S Imani","year":"2017","unstructured":"Imani S, Zhang X, Hosseinifard H, Fu S, Fu J. The diagnostic role of microrna-34a in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(14):23177\u201387.","journal-title":"Oncotarget"},{"key":"1892_CR192","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.17.585428","author":"Q Zhu","year":"2024","unstructured":"Zhu Q, Balasubramanian A, Asirvatham JR, Piyarathna B, Kaur J, Mohamed N, et al. Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in African American and European American patients with TNBC. Nat Commun. 2024. https:\/\/doi.org\/10.1101\/2024.03.17.585428.","journal-title":"Nat Commun"},{"key":"1892_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1137464\/full","author":"X Liang","year":"2023","unstructured":"Liang X, Chen X, Li H, Li Y. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1137464\/full.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1892_CR194","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/CCO.0000000000000878","volume":"34","author":"E Mezni","year":"2022","unstructured":"Mezni E, Behi K, Gon\u00e7alves A. Immunotherapy and breast cancer: an overview. Curr Opin Oncol. 2022;34(5):587\u201394. https:\/\/doi.org\/10.1097\/CCO.0000000000000878.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"1892_CR195","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/CJI.0000000000000384","volume":"44","author":"DJ Ralser","year":"2021","unstructured":"Ralser DJ, Kl\u00fcmper N, Gevensleben H, Zarbl R, Kaiser C, Landsberg J, et al. Molecular and immune correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA methylation in triple negative breast cancer. J Immunother. 2021;44(8):319\u201324. https:\/\/doi.org\/10.1097\/CJI.0000000000000384.","journal-title":"J Immunother"},{"issue":"1","key":"1892_CR196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s43856-023-00311-y","volume":"3","author":"M Ensenyat-Mendez","year":"2023","unstructured":"Ensenyat-Mendez M, Orozco JIJ, Llin\u00e0s-Arias P, \u00cd\u00f1iguez-Mu\u00f1oz S, Baker JL, Salomon MP, et al. Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer. Commun Med. 2023;3(1):93.","journal-title":"Commun Med"},{"issue":"7","key":"1892_CR197","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jamaoncol.2021.1254","volume":"7","author":"B Cho","year":"2021","unstructured":"Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, et al. Evaluation of racial\/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol. 2021;7(7):1016.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1892_CR198","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-016-4062-y","volume":"161","author":"FO Ademuyiwa","year":"2017","unstructured":"Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. Breast Cancer Res Treat. 2017;161(3):491\u20139. https:\/\/doi.org\/10.1007\/s10549-016-4062-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1892_CR199","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3896","volume":"15","author":"EC Dietze","year":"2015","unstructured":"Dietze EC, Sistrunk C, Miranda-Carboni G, O\u2019Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15(4):248\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1892_CR200","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1158\/1940-6207.CAPR-19-0562","volume":"13","author":"JW Ogony","year":"2020","unstructured":"Ogony JW, Radisky DC, Ruddy KJ, Goodison S, Wickland DP, Egan KM, et al. Immune responses and risk of triple-negative breast cancer: implications for higher rates among African American women. Cancer Prev Res. 2020;13(11):901\u201310.","journal-title":"Cancer Prev Res"},{"issue":"10","key":"1892_CR201","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ccell.2022.08.022","volume":"40","author":"AH Nassar","year":"2022","unstructured":"Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022;40(10):1161-1172.e5.","journal-title":"Cancer Cell"},{"issue":"1","key":"1892_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02777-9","volume":"4","author":"J O\u2019Connell","year":"2021","unstructured":"O\u2019Connell J, Yun T, Moreno M, Li H, Litterman N, Kolesnikov A, et al. A population-specific reference panel for improved genotype imputation in African Americans. Commun Biol. 2021;4(1):1269.","journal-title":"Commun Biol"},{"issue":"25","key":"1892_CR203","doi-asserted-by":"publisher","first-page":"40222","DOI":"10.18632\/oncotarget.16712","volume":"8","author":"M Cui","year":"2017","unstructured":"Cui M, Gao X, Gu X, Guo W, Li X, Ma M, et al. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8988 patients with prostate cancer. Oncotarget. 2017;8(25):40222\u201332. https:\/\/doi.org\/10.18632\/oncotarget.16712.","journal-title":"Oncotarget"},{"issue":"8","key":"1892_CR204","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891","volume":"9","author":"VM Negrao","year":"2021","unstructured":"Negrao VM, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021;9(8):e002891. https:\/\/doi.org\/10.1136\/jitc-2021-002891.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1892_CR205","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3233\/CBM-220030","volume":"36","author":"K M\u00f6ller","year":"2023","unstructured":"M\u00f6ller K, Kn\u00f6ll M, Bady E, Schmerder MJ, Rico SD, Kluth M, et al. PD-L1 expression and CD8 positive lymphocytes in human neoplasms: a tissue microarray study on 11,838 tumor samples. Cancer Biomark. 2023;36(2):177\u201391. https:\/\/doi.org\/10.3233\/CBM-220030.","journal-title":"Cancer Biomark"},{"issue":"4","key":"1892_CR206","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ng.3521","volume":"48","author":"A Dunning","year":"2016","unstructured":"Dunning A, Michailidou K, Kuchenbaecker K, Thompson D, French J, Beesley J, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1, and CCDC170. Nat Genet. 2016;48(4):374\u201386. https:\/\/doi.org\/10.1038\/ng.3521.","journal-title":"Nat Genet"},{"issue":"1","key":"1892_CR207","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.clbc.2019.06.014","volume":"20","author":"Q Du","year":"2020","unstructured":"Du Q, Che J, Jiang X, Li L, Luo X, Li Q. PD-L1 acts as a promising immune marker to predict the response to neoadjuvant chemotherapy in breast cancer patients. Clin Breast Cancer. 2020;20(1):e99\u2013111. https:\/\/doi.org\/10.1016\/j.clbc.2019.06.014.","journal-title":"Clin Breast Cancer"},{"key":"1892_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1475979\/full","author":"D Zhao","year":"2024","unstructured":"Zhao D, Yu X, Huang H, Zou S, Zhu P, Lin Y, et al. Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case\u2013control study in China. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1475979\/full.","journal-title":"Front Oncol"},{"key":"1892_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1102-7","author":"B Lehmann","year":"2015","unstructured":"Lehmann B, Ding Y, Viox D, Jiang M, Zheng Y, Liao W, et al. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer. 2015. https:\/\/doi.org\/10.1186\/s12885-015-1102-7.","journal-title":"BMC Cancer"},{"issue":"1","key":"1892_CR210","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2015","unstructured":"Zhong Q, Peng H, Zhao X, Zhang L, Hwang W. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21(1):211\u201320.","journal-title":"Clin Cancer Res"},{"key":"1892_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10729-9","author":"X He","year":"2017","unstructured":"He X, Zou D. The association of young age with local recurrence in women with early-stage breast cancer after breast-conserving therapy: a meta-analysis. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/s41598-017-10729-9.","journal-title":"Sci Rep"},{"issue":"9","key":"1892_CR212","doi-asserted-by":"publisher","first-page":"15815","DOI":"10.18632\/oncotarget.15012","volume":"8","author":"S Wang","year":"2017","unstructured":"Wang S, Du H, Li G. Significant prognostic value of circulating tumor cells in esophageal cancer patients: a meta-analysis. Oncotarget. 2017;8(9):15815\u201326.","journal-title":"Oncotarget"},{"key":"1892_CR213","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1200\/GO.21.00309","volume":"7","author":"OW Brawley","year":"2021","unstructured":"Brawley OW, Luhn P, Reese-White D, Ogbu UC, Madhavan S, Wilson G, et al. Disparities in tumor mutational burden, immunotherapy use, and outcomes based on genomic ancestry in non-small-cell lung cancer. JCO Glob Oncol. 2021;7:1537\u201346.","journal-title":"JCO Glob Oncol"},{"issue":"16","key":"1892_CR214","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1002\/cncr.28168","volume":"119","author":"K Kwiatkowski","year":"2013","unstructured":"Kwiatkowski K, Coe K, Bailar JC, Swanson GM. Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? Cancer. 2013;119(16):2956\u201363.","journal-title":"Cancer"},{"key":"1892_CR215","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0647-4","author":"L Fancello","year":"2019","unstructured":"Fancello L, Gandini S, Pelicci P, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019. https:\/\/doi.org\/10.1186\/s40425-019-0647-4.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1892_CR216","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031310","volume":"22","author":"C Herrera-Pariente","year":"2021","unstructured":"Herrera-Pariente C, Cap\u00f3-Garc\u00eda R, D\u00edaz-Gay M, Carballal S, Mu\u00f1oz J, Llach J, et al. Identification of new genes involved in germline predisposition to early-onset gastric cancer. Int J Mol Sci. 2021;22(3):1310.","journal-title":"Int J Mol Sci"},{"key":"1892_CR217","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2020.01.019","volume":"142","author":"J Budczies","year":"2020","unstructured":"Budczies J, Kazdal D, Allg\u00e4uer M, Christopoulos P, Rempel E, Pfarr N, et al. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer. 2020;142:114\u20139.","journal-title":"Lung Cancer"},{"key":"1892_CR218","unstructured":"Ranade K, Higgs BW, Raja RG, Brohawn PZ, Si H, KUZIORA MA. Blood-based tumor mutation burden predicts overall survival in nsclc [Internet]. 2023. Available from: https:\/\/patents.google.com\/patent\/US20230145764A1\/en."},{"issue":"13_Supplement","key":"1892_CR219","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/1538-7445.AM2019-1701","volume":"79","author":"W Tom","year":"2019","unstructured":"Tom W, Chaudhary R, Mittal V, Cyanam D, Casuga I, Wong-Ho E, et al. Abstract 1701: improvement of tumor mutation burden measurement by removal of deaminated bases in FFPE DNA. Cancer Res. 2019;79(13_Supplement):1701\u20131701.","journal-title":"Cancer Res"},{"issue":"2","key":"1892_CR220","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001199","volume":"8","author":"TH Hong","year":"2020","unstructured":"Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, et al. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. J Immunother Cancer. 2020;8(2):e001199. https:\/\/doi.org\/10.1136\/jitc-2020-001199.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1892_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00504-1","volume":"8","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang D, Zhao Z, Peng R, Han Y, Li J, et al. Enhancing the quality of panel-based tumor mutation burden assessment: a comprehensive study of real-world and in-silico outcomes. NPJ Precis Oncol. 2024;8(1):18.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"1892_CR222","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.21037\/jtd.2019.05.68","volume":"11","author":"VK Lam","year":"2019","unstructured":"Lam VK, Zhang J. Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer. J Thorac Dis. 2019;11(6):2208\u201311.","journal-title":"J Thorac Dis"},{"issue":"3","key":"1892_CR223","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/gcc.23100","volume":"62","author":"E Raiber-Moreau","year":"2023","unstructured":"Raiber-Moreau E, Portella G, Butler MG, Clement O, Konigshofer Y, Hadfield J. Development and validation of blood tumor mutational burden reference standards. Genes Chromosomes Cancer. 2023;62(3):121\u201330. https:\/\/doi.org\/10.1002\/gcc.23100.","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"1892_CR224","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007339","volume":"11","author":"J He","year":"2023","unstructured":"He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, et al. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high T. J Immunother Cancer. 2023;11(11):e007339. https:\/\/doi.org\/10.1136\/jitc-2023-007339.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1892_CR225","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jtho.2020.01.023","volume":"15","author":"A Stenzinger","year":"2020","unstructured":"Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, et al. Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study. J Thorac Oncol. 2020;15(7):1177\u201389.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"1892_CR226","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236033","volume":"13","author":"S Martinez-Pacheco","year":"2021","unstructured":"Martinez-Pacheco S, O\u2019Driscoll L. Pre-clinical in vitro models used in cancer research: results of a worldwide survey. Cancers (Basel). 2021;13(23):6033.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1892_CR227","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-023-02653-w","volume":"42","author":"P Mu","year":"2023","unstructured":"Mu P, Zhou S, Lv T, Fan X, Shen L, Wan J, et al. Newly developed 3d in vitro models to study tumor\u2013immune interaction. J Exp Clin Cancer Res. 2023;42(1):81.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"1892_CR228","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/bit.26297","volume":"114","author":"G Chiew","year":"2017","unstructured":"Chiew G, Wei N, Sultania S, Lim S, Luo K. Bioengineered three-dimensional co-culture of cancer cells and endothelial cells: a model system for dual analysis of tumor growth and angiogenesis. Biotechnol Bioeng. 2017;114(8):1865\u201377.","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"1892_CR229","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/8\/2\/025002","volume":"8","author":"M Alonso-Nocelo","year":"2016","unstructured":"Alonso-Nocelo M, Abu\u00edn C, L\u00f3pez-L\u00f3pez R, Fuente M. Development and characterization of a three-dimensional co-culture model of tumor t cell infiltration. Biofabrication. 2016;8(2):25002.","journal-title":"Biofabrication"},{"issue":"6","key":"1892_CR230","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1002\/mco2.437","volume":"4","author":"H Xu","year":"2023","unstructured":"Xu H. Biomarkers and experimental models for cancer immunology investigation. MedComm. 2023;4(6):e437.","journal-title":"MedComm"},{"key":"1892_CR231","first-page":"10","volume":"160","author":"Y Lin","year":"2020","unstructured":"Lin Y, Nasir A, Camacho S, Berry D, Schmidt M, Pearson G, et al. Monitoring cancer cell invasion and t-cell cytotoxicity in 3d culture. J Vis Exp. 2020;160:10\u20133791.","journal-title":"J Vis Exp"},{"key":"1892_CR232","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1244159\/full","author":"F Hossain","year":"2023","unstructured":"Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, et al. Sulindac sulfide as a non-immune suppressive \u03b3-secretase modulator to target triple-negative breast cancer. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1244159\/full.","journal-title":"Front Immunol"},{"issue":"8","key":"1892_CR233","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s12094-019-02276-8","volume":"22","author":"H Liu","year":"2020","unstructured":"Liu H, Xia B, Jin M, Lou G. Organoid of ovarian cancer: genomic analysis and drug screening. Clin Transl Oncol. 2020;22(8):1240\u201351.","journal-title":"Clin Transl Oncol"},{"key":"1892_CR234","doi-asserted-by":"publisher","first-page":"1343177","DOI":"10.3389\/fbioe.2023.1343177","volume":"11","author":"L Zhu","year":"2023","unstructured":"Zhu L. Advancements and application prospects of three-dimensional models for primary liver cancer: a comprehensive review. Front Bioeng Biotechnol. 2023;11:1343177.","journal-title":"Front Bioeng Biotechnol"},{"issue":"8","key":"1892_CR235","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/gcc.22733","volume":"58","author":"A Stenzinger","year":"2019","unstructured":"Stenzinger A, Allen JD, Maas J, Stewart MD, Merino DM, Wempe MM, et al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019;58(8):578\u201388. https:\/\/doi.org\/10.1002\/gcc.22733.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"1892_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183. https:\/\/doi.org\/10.1186\/s40425-019-0647-4.","journal-title":"J Immunother Cancer"},{"key":"1892_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102084","volume":"89","author":"MG McNamara","year":"2020","unstructured":"McNamara MG, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev. 2020;89:102084.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"1892_CR238","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095097","volume":"23","author":"MT Sung","year":"2022","unstructured":"Sung MT, Wang YH, Li CF. Open the technical black box of tumor mutational burden (TMB): factors affecting harmonization and standardization of panel-based TMB. Int J Mol Sci. 2022;23(9):5097.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1892_CR239","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.jtho.2020.05.013","volume":"15","author":"S Heeke","year":"2020","unstructured":"Heeke S, Benzaquen J, Hofman V, Long-Mira E, Lespinet V, Bordone O, et al. Comparison of three sequencing panels used for the assessment of tumor mutational burden in NSCLC reveals low comparability. J Thorac Oncol. 2020;15(9):1535\u201340.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1892_CR240","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010230","volume":"12","author":"H Noskov\u00e1","year":"2020","unstructured":"Noskov\u00e1 H, K\u00fdr M, P\u00e1l K, Merta T, M\u00fadr\u00fd P, Polaskova K, et al. Assessment of tumor mutational burden in pediatric tumors by real-life whole-exome sequencing and in silico simulation of targeted gene panels: how the choice of method could affect the clinical decision? Cancers (Basel). 2020;12(1):230.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1892_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005801","volume":"11","author":"R Huang","year":"2023","unstructured":"Huang R, Carbone D, Li G, Schrock A, Graf R, Zhang L, et al. Durable responders in advanced nsclc with elevated tmb and treated with 1l immune checkpoint inhibitor: a real-world outcomes analysis. J Immunother Cancer. 2023;11(1):e005801.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1892_CR242","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003087","volume":"10","author":"M Zheng","year":"2022","unstructured":"Zheng M. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. J Immunother Cancer. 2022;10(1):e003087.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1892_CR243","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-20-3771","volume":"27","author":"H Si","year":"2020","unstructured":"Si H, Kuziora M, Quinn K, Helman E, Ye J, Liu F, et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic nsclc treatment: results from the mystic study. Clin Cancer Res. 2020;27(6):1631\u201340.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1892_CR244","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245841","volume":"15","author":"J Ahmed","year":"2023","unstructured":"Ahmed J. Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers (Basel). 2023;15(24):5841.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1892_CR245","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.21873\/anticanres.14868","volume":"41","author":"G Pian","year":"2021","unstructured":"Pian G, Shin J, Yoon S, Oh S. Prognostic reappraisal of postoperative carcinoembryonic antigen in T1\u20132N0 colorectal cancer. Anticancer Res. 2021;41(2):1101\u201310.","journal-title":"Anticancer Res"},{"issue":"1","key":"1892_CR246","doi-asserted-by":"publisher","first-page":"28","DOI":"10.48095\/ccko202328","volume":"36","author":"V Tanco\u0161","year":"2023","unstructured":"Tanco\u0161 V, Blich\u00e1rov\u00e1 A. Predictive biomarkers of response to immunotherapy in triple-negative breast cancer\u2014state of the art and future perspectives. Klin Onkol. 2023;36(1):28.","journal-title":"Klin Onkol"},{"issue":"11","key":"1892_CR247","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260206","volume":"16","author":"F Mazerolles","year":"2021","unstructured":"Mazerolles F, Rieux-Laucat F. PD-L1 is expressed on human activated naive effector CD4+ T cells. Regulation by dendritic cells and regulatory CD4+ T cells. PLoS ONE. 2021;16(11):e0260206. https:\/\/doi.org\/10.1371\/journal.pone.0260206.","journal-title":"PLoS ONE"},{"issue":"1","key":"1892_CR248","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11(1):4835.","journal-title":"Nat Commun"},{"key":"1892_CR249","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.593848\/full","author":"A Jim\u00e9nez-Reinoso","year":"2021","unstructured":"Jim\u00e9nez-Reinoso A, Nehme-\u00c1lvarez D, Dom\u00ednguez-Alonso C, \u00c1lvarez-Vallina L. Synthetic TILs: engineered tumor-infiltrating lymphocytes with improved therapeutic potential. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2020.593848\/full.","journal-title":"Front Oncol"},{"issue":"21","key":"1892_CR250","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215433","volume":"14","author":"CB Xavier","year":"2022","unstructured":"Xavier CB, Lopes CDH, Awni BM, Campos EF, Alves JPB, Camargo AA, et al. Interplay between tumor mutational burden and mutational profile and its effect on overall survival: a pilot study of metastatic patients treated with immune checkpoint inhibitors. Cancers (Basel). 2022;14(21):5433.","journal-title":"Cancers (Basel)"},{"key":"1892_CR251","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142513","author":"CC Balan\u00e7a","year":"2021","unstructured":"Balan\u00e7a CC, Salvioni A, Scarlata CM, Michelas M, Martinez-Gomez C, Gomez-Roca C, et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.142513.","journal-title":"JCI Insight"},{"issue":"7870","key":"1892_CR252","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EHC, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021;596(7870):126\u201332.","journal-title":"Nature"},{"issue":"1","key":"1892_CR253","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13058-022-01531-1","volume":"24","author":"M Harrasser","year":"2022","unstructured":"Harrasser M, Gohil SH, Lau H, Della Peruta M, Muczynski V, Patel D, et al. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. Breast Cancer Res. 2022;24(1):39. https:\/\/doi.org\/10.1186\/s13058-022-01531-1.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1892_CR254","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2018","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2018;7(1):e1364828. https:\/\/doi.org\/10.1080\/2162402X.2017.1364828.","journal-title":"Oncoimmunology"},{"issue":"11","key":"1892_CR255","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013940","volume":"5","author":"LT Nguyen","year":"2010","unstructured":"Nguyen LT, Yen PH, Nie J, Liadis N, Ghazarian D, Al-Habeeb A, et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS ONE. 2010;5(11):e13940. https:\/\/doi.org\/10.1371\/journal.pone.0013940.","journal-title":"PLoS ONE"},{"issue":"1","key":"1892_CR256","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4049\/jimmunol.0901101","volume":"184","author":"Y Li","year":"2010","unstructured":"Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1\u2013specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol. 2010;184(1):452\u201365.","journal-title":"J Immunol"},{"issue":"19","key":"1892_CR257","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","volume":"26","author":"M Galsky","year":"2020","unstructured":"Galsky M, Saci A, Szab\u00f3 P, Han G, Grossfeld G, Collette S, et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkmate 275. Clin Cancer Res. 2020;26(19):5120\u20138.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1892_CR258","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-19-0558","volume":"25","author":"L Liu","year":"2019","unstructured":"Liu L, Bai X, Wang J, Tang X, Wu D, Du S, et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res. 2019;25(24):7413\u201323.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1892_CR259","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/cancers11091270","volume":"11","author":"A Argentiero","year":"2019","unstructured":"Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, et al. Skeletal metastases of unknown primary: biological landscape and clinical overview. Cancers (Basel). 2019;11(9):1270.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1892_CR260","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40291-019-00408-y","volume":"23","author":"C Han","year":"2019","unstructured":"Han C, Sasson A, Srinivasan S, Golhar R, Greenawalt D, Geese W, et al. Bioinformatic methods and bridging of assay results for reliable tumor mutational burden assessment in non-small-cell lung cancer. Mol Diagn Ther. 2019;23(4):507\u201320.","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"1892_CR261","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/genes12081206","volume":"12","author":"MA Shadbad","year":"2021","unstructured":"Shadbad MA, Safaei S, Brunetti O, Derakhshani A, Lotfinejad P, Mokhtarzadeh A, et al. A systematic review on the therapeutic potentiality of PD-L1-inhibiting microRNAs for triple-negative breast cancer: toward single-cell sequencing-guided biomimetic delivery. Genes (Basel). 2021;12(8):1206.","journal-title":"Genes (Basel)"},{"issue":"8","key":"1892_CR262","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009774","volume":"12","author":"C Vaxevanis","year":"2024","unstructured":"Vaxevanis C, Bachmann M, Seliger B. Immune modulatory micrornas in tumors, their clinical relevance in diagnosis and therapy. J Immunother Cancer. 2024;12(8):e009774. https:\/\/doi.org\/10.1136\/jitc-2024-009774.","journal-title":"J Immunother Cancer"},{"key":"1892_CR263","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1226","author":"M Wang","year":"2020","unstructured":"Wang M, Wang S, Desai J, Trapani JA, Neeson PJ. Therapeutic strategies to remodel immunologically cold tumors. Clin Transl Immunol. 2020. https:\/\/doi.org\/10.1002\/cti2.1226.","journal-title":"Clin Transl Immunol"},{"key":"1892_CR264","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01214\/full","author":"E Daveri","year":"2020","unstructured":"Daveri E, Vergani E, Shahaj E, Bergamaschi L, La Magra S, Dosi M, et al. microRNAs shape myeloid cell-mediated resistance to cancer immunotherapy. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.01214\/full.","journal-title":"Front Immunol"},{"issue":"21","key":"1892_CR265","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.3390\/cancers13215301","volume":"13","author":"RAS Sloane","year":"2021","unstructured":"Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, et al. Identification of microRNA\u2013mRNA networks in melanoma and their association with PD-1 checkpoint blockade outcomes. Cancers (Basel). 2021;13(21):5301.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"1892_CR266","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.3390\/ijms21155353","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H. MicroRNAs and apoptosis in colorectal cancer. Int J Mol Sci. 2020;21(15):5353.","journal-title":"Int J Mol Sci"},{"key":"1892_CR267","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862502\/full","author":"K Fang","year":"2022","unstructured":"Fang K, Tang DS, Yan CS, Ma J, Cheng L, Li Y, et al. Comprehensive analysis of necroptosis in pancreatic cancer for appealing its implications in prognosis, immunotherapy, and chemotherapy responses. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.862502\/full.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1892_CR268","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","volume":"128","author":"RJ Walsh","year":"2023","unstructured":"Walsh RJ, Sundar R, Lim JSJ. Immune checkpoint inhibitor combinations\u2014current and emerging strategies. Br J Cancer. 2023;128(8):1415\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"1892_CR269","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02407-8","volume":"22","author":"S Vafaei","year":"2022","unstructured":"Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22(1):2. https:\/\/doi.org\/10.1186\/s12935-021-02407-8.","journal-title":"Cancer Cell Int"},{"key":"1892_CR270","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1325615\/full","author":"J Yin","year":"2024","unstructured":"Yin J, Gu T, Chaudhry N, Davidson NE, Huang Y. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2023.1325615\/full.","journal-title":"Front Immunol"},{"issue":"1","key":"1892_CR271","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22(1):145. https:\/\/doi.org\/10.1186\/s12943-023-01850-7.","journal-title":"Mol Cancer"},{"key":"1892_CR272","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.870914\/full","author":"M Xu","year":"2022","unstructured":"Xu M, Lu J, Zhong Y, Jiang J, Shen Y, Su J, et al. Immunogenic cell death-relevant damage-associated molecular patterns and sensing receptors in triple-negative breast cancer molecular subtypes and implications for immunotherapy. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.870914\/full.","journal-title":"Front Oncol"},{"issue":"1","key":"1892_CR273","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41392-021-00707-z","volume":"6","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wang B, Cao X. Epigenetic checkpoint blockade: new booster for immunotherapy. Signal Transduct Target Ther. 2021;6(1):281.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"1892_CR274","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.3390\/molecules28155804","volume":"28","author":"LLY Kan","year":"2023","unstructured":"Kan LLY, Chan BCL, Leung PC, Wong CK. Natural-product-derived adjunctive treatments to conventional therapy and their immunoregulatory activities in triple-negative breast cancer. Molecules. 2023;28(15):5804.","journal-title":"Molecules"},{"issue":"1","key":"1892_CR275","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","volume":"38","author":"J Qin","year":"2019","unstructured":"Qin J, Li Y, Zhang J, Zhang W. Stat3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38(1):195.","journal-title":"J Exp Clin Cancer Res"},{"key":"1892_CR276","doi-asserted-by":"publisher","first-page":"574752","DOI":"10.3389\/fonc.2020.574752","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Yan S, Yang J, Wang Y, Lv C, Li S, et al. Efficacy and safety of pd-1\/pd-l1 inhibitors plus chemotherapy versus pd-1\/pd-l1 inhibitors in advanced non-small cell lung cancer: a network analysis of randomized controlled trials. Front Oncol. 2021;10:574752.","journal-title":"Front Oncol"},{"issue":"5","key":"1892_CR277","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1002\/jcp.29371","volume":"235","author":"C Wang","year":"2019","unstructured":"Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T, et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cell Physiol. 2019;235(5):4913\u201327.","journal-title":"J Cell Physiol"},{"issue":"20","key":"1892_CR278","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1158\/1078-0432.CCR-19-1105","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Han SW, Bae JM, Jang H, Han H, Kim H, et al. Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin. Clin Cancer Res. 2019;25(20):6141\u20137.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1892_CR279","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1158\/1055-9965.EPI-22-0630","volume":"31","author":"LJ Ruel","year":"2022","unstructured":"Ruel LJ, Li Z, Gaudreault N, Henry C, Saavedra Armero V, Boudreau DK, et al. Tumor mutational burden by whole-genome sequencing in resected NSCLC of never smokers. Cancer Epidemiol Biomarkers Prev. 2022;31(12):2219\u201327.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1892_CR280","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12876-022-02112-4","volume":"22","author":"W Li","year":"2022","unstructured":"Li W, Zhou K, Li M, Hu Q, Wei W, Liu L, et al. Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer. BMC Gastroenterol. 2022;22(1):45. https:\/\/doi.org\/10.1186\/s12876-022-02112-4.","journal-title":"BMC Gastroenterol"},{"key":"1892_CR281","doi-asserted-by":"publisher","first-page":"662731","DOI":"10.3389\/fonc.2021.662731","volume":"11","author":"K Liu","year":"2021","unstructured":"Liu K, Qin Z, Xu X, Li T, Ge Y, Mao H, et al. Comparative risk of renal adverse events in patients receiving immune checkpoint inhibitors: a Bayesian network meta-analysis. Front Oncol. 2021;11:662731.","journal-title":"Front Oncol"},{"key":"1892_CR282","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fonc.2020.00197","volume":"10","author":"W Yang","year":"2020","unstructured":"Yang W, Men P, Xue H, Jiang M, Luo Q. Risk of gastrointestinal adverse events in cancer patients treated with immune checkpoint inhibitor plus chemotherapy: a systematic review and meta-analysis. Front Oncol. 2020;10:197.","journal-title":"Front Oncol"},{"issue":"11","key":"1892_CR283","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s00262-021-02996-3","volume":"70","author":"E Suazo-Zepeda","year":"2021","unstructured":"Suazo-Zepeda E, Bokern M, Vinke P, Hiltermann T, Bock G, Sidorenkov G. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother. 2021;70(11):3069\u201380.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1892_CR284","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.18632\/aging.202724","volume":"13","author":"F Shao","year":"2021","unstructured":"Shao F, Duan Y, Zhao Y, Li Y, Li J, Zhang C, et al. Parp inhibitors in breast and ovarian cancer with brca mutations: a meta-analysis of survival. Aging (Albany NY). 2021;13(6):8975\u201388.","journal-title":"Aging (Albany NY)"},{"key":"1892_CR285","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/1780860","volume":"2021","author":"Z Nan","year":"2021","unstructured":"Nan Z, Guoqing W, Xiaoxu Y, Yin M, Xin H, Xue L, et al. The Predictive efficacy of tumor mutation burden (TMB) on nonsmall cell lung cancer treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:1\u201313.","journal-title":"Biomed Res Int"},{"key":"1892_CR286","doi-asserted-by":"publisher","first-page":"603157","DOI":"10.3389\/fimmu.2020.603157","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Zhang C, Pang G, Wang P. Emerging blood-based biomarkers for predicting response to checkpoint immunotherapy in non-small-cell lung cancer. Front Immunol. 2020;11:603157.","journal-title":"Front Immunol"},{"issue":"23","key":"1892_CR287","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1158\/0008-5472.CAN-12-3232","volume":"72","author":"SE Kern","year":"2012","unstructured":"Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012;72(23):6097\u2013101.","journal-title":"Cancer Res"},{"issue":"19","key":"1892_CR288","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-18-4159","volume":"25","author":"TC Knepper","year":"2019","unstructured":"Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, et al. The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 2019;25(19):5961\u201371.","journal-title":"Clin Cancer Res"},{"key":"1892_CR289","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.2147\/IJGM.S352851","volume":"15","author":"Z Li","year":"2022","unstructured":"Li Z, Feng Y, Li P, Wang S, Liu X, Xia S. CD1B is a potential prognostic biomarker associated with tumor mutation burden and promotes antitumor immunity in lung adenocarcinoma. Int J Gen Med. 2022;15:3809\u201326.","journal-title":"Int J Gen Med"},{"issue":"3","key":"1892_CR290","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mc.23368","volume":"61","author":"X Chen","year":"2022","unstructured":"Chen X, Ou Z, Wang L, Zhang Z, Fan X, Liu H, et al. Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma. Mol Carcinog. 2022;61(3):311\u201321.","journal-title":"Mol Carcinog"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01892-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:08:51Z","timestamp":1763446131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01892-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":290,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01892-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that the data compilation and analysis was conducted in the absence of any competing commercial or financial matters that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"25"}}